Arya Sciences Acquisition II competed the merger with Cerevel Therapeutics in a $1.3bn deal.

Arya Sciences Acquisition II, a blank check company completed the merger with Cerevel Therapeutics, a clinical-stage biopharmaceutical company, in a $1.3bn deal. In addition a group of investors led by Bain Capital, Perceptive Advisors and Pfizer has committed to participate in the transaction through a common stock PIPE of approximately $320m at $10 per share. “We believe Cerevel is positioned to open new frontiers in neuroscience, making it precisely the type of opportunity that Arya II was designed to combine with. We are excited about the potential in the Cerevel pipeline – for both patients and investors. We look forward to partnering with Tony and his team as they advance their pipeline of differentiated neuroscience assets," Adam Stone, Perceptive Advisors Chief Investment Officer and Arya II CEO.